Literature DB >> 7822089

Treatment of oral pemphigus vulgaris.

F Chrysomallis1, D Ioannides, A Teknetzis, D Panagiotidou, A Minas.   

Abstract

BACKGROUND: Oral pemphigus is considered to represent either an initial stage of pemphigus vulgaris that should be treated with high doses of immunosuppressive drugs to prevent its spread to the skin or a variety of the disease that does not need aggressive treatment. The absence of a widely accepted therapeutic method and the obscure nature of this disease prompted this study.
METHODS: Twenty-eight patients with oral pemphigus were randomly divided into three groups. The first group received only steroids at a dose of 40 mg of prednisone equivalent. In the other two groups the same dose of steroids was administered, but combined with either 100 mg of cyclophosphamide or 5 mg/kg of cyclosporine as an adjuvant. Direct immunofluorescence studies were performed on specimens obtained from both buccal mucosa and oral skin.
RESULTS: There was no significant difference in the duration of treatment required to achieve remission and in the relapse rate among the three groups. The incidence of complications was higher with combination treatment. Deposited immunoreactants were detected with equal frequency in specimens obtained from the buccal mucosa and normal skin.
CONCLUSIONS: Oral pemphigus most likely represents an initial stage of a disease that can become generalized. Administration of moderate doses of steroids alone is effective in controlling the disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7822089     DOI: 10.1111/j.1365-4362.1994.tb01003.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  8 in total

Review 1.  Pemphigus vulgaris: an evidence-based treatment update.

Authors:  Cathy Y Zhao; Dedee F Murrell
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

2.  [Gold. Effective therapy for mucosal lesions of pemphigus vulgaris].

Authors:  D Lange; F Meiss; E Fiedler; K Treiber; W C Marsch; M Fischer
Journal:  Hautarzt       Date:  2007-02       Impact factor: 0.751

3.  Survival of Adjuvant Drugs for Treatment of Pemphigus: A Population-based Cohort Study.

Authors:  Khalaf Kridin; Christoph M Hammers; Ralf J Ludwig; Dana Tzur Bitan; Arnon D Cohen
Journal:  Acta Derm Venereol       Date:  2021-09-03       Impact factor: 3.875

Review 4.  Management of pemphigus.

Authors:  Benjamin S Daniel; Dedee F Murrell
Journal:  F1000Prime Rep       Date:  2014-05-06

Review 5.  Pemphigus: Current and Future Therapeutic Strategies.

Authors:  Dario Didona; Roberto Maglie; Rüdiger Eming; Michael Hertl
Journal:  Front Immunol       Date:  2019-06-25       Impact factor: 7.561

Review 6.  Management of pemphigus vulgaris: challenges and solutions.

Authors:  Stamatis Gregoriou; Ourania Efthymiou; Christina Stefanaki; Dimitris Rigopoulos
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-10-21

7.  A Comparative Effectiveness Research of Azathioprine and Cyclophosphamide on the Clinical and Serological Response in Pemphigus Vulgaris.

Authors:  Kabir Sardana; Pooja Agarwal; Shivani Bansal; Beena Uppal; Vijay K Garg
Journal:  Indian J Dermatol       Date:  2016 Jul-Aug       Impact factor: 1.494

Review 8.  Emerging treatment options for the management of pemphigus vulgaris.

Authors:  Khalaf Kridin
Journal:  Ther Clin Risk Manag       Date:  2018-04-27       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.